Jia Ruan, M.D., Ph.D. | Patient Care

Dr. Jia Ruan, M.D., Ph.D.

Claim this profile

NYP/Weill Cornell Medical Center

Studies Lymphoma
Studies Mycosis Fungoides and Sezary Syndrome
6 reported clinical trials
15 drugs studied

Area of expertise

1Lymphoma
Jia Ruan, M.D., Ph.D. has run 2 trials for Lymphoma. Some of their research focus areas include:
Stage IV
CD3 positive
CD2 positive
2Mycosis Fungoides And Sezary Syndrome
Jia Ruan, M.D., Ph.D. has run 2 trials for Mycosis Fungoides and Sezary Syndrome. Some of their research focus areas include:
Stage II
Stage III
Stage IV

Affiliated Hospitals

Image of trial facility.
NYP/Weill Cornell Medical Center
Image of trial facility.
Weill Cornell Medicine

Clinical Trials Jia Ruan, M.D., Ph.D. is currently running

Image of trial facility.

Lenalidomide + EPOCH Chemotherapy

for Adult T-Cell Leukemia-Lymphoma

This phase I trial studies the side effects and best dose of lenalidomide when given together with usual combination chemotherapy (etoposide, prednisone, vincristine sulfate \[Oncovin\], cyclophosphamide, and doxorubicin hydrochloride \[hydroxydaunorubicin hydrochloride\], or "EPOCH") in treating adult T-cell leukemia-lymphoma. Lenalidomide may help shrink or slow the growth of adult T-cell leukemia-lymphoma. Drugs used in chemotherapy, such as etoposide, vincristine, cyclophosphamide, and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs such as prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving lenalidomide and the usual combination chemotherapy may work better in treating adult T-cell leukemia-lymphoma compared to the usual combination chemotherapy alone.
Recruiting1 award Phase 1
Image of trial facility.

Zanubrutinib

for Mantle Cell Lymphoma

This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated). Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. When zanubrutinib is used in MCL, the current standard of care is to continue administering the drug indefinitely until disease progression. This continuous treatment comes with clinical as well as financial toxicity, which could be especially detrimental in older patients. For patients who achieve a CR after initial zanubrutinib plus rituximab therapy, it may be safe and equally effective to stop treatment and restart zanubrutinib upon disease progression rather than continuing indefinitely in previously untreated older adult patients with MCL.
Recruiting2 awards Phase 310 criteria

More about Jia Ruan, M.D., Ph.D.

Clinical Trial Related4 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Jia Ruan, M.D., Ph.D. has experience with
  • Lenalidomide
  • Prednisone
  • Duvelisib
  • Cyclophosphamide; Doxorubicin Hydrochloride; Etoposide; Vincristine Sulfate
  • Nivolumab
  • CC-486

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Jia Ruan, M.D., Ph.D. specialize in?
Is Jia Ruan, M.D., Ph.D. currently recruiting for clinical trials?
Are there any treatments that Jia Ruan, M.D., Ph.D. has studied deeply?
What is the best way to schedule an appointment with Jia Ruan, M.D., Ph.D.?
What is the office address of Jia Ruan, M.D., Ph.D.?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security